Breaking News

Aduro, Janssen Ink Immunotherapies License Agreement

May 29, 2014

Janssen to take on prostate cancer candidates

Aduro BioTech, Inc. has entered an agreement granting Janssen Biotech an exclusive, worldwide license to certain product candidates for the treatment of prostate cancer based on its LADD immunotherapy platform.
Aduro is eligible to receive as much as $365 million in upfront license fees and milestone payments based on development, regulatory and commercialization milestones, should multiple programs advance to commercialization, as well as royalties on sales.
Janssen will be responsible for all research, development, manufacturing, regulatory and commercialization for the licensed products. Under a separate agreement, Aduro has granted Janssen exclusive rights to its GVAX technology for prostate cancer.
“We are pleased to provide Janssen with novel immunotherapies engineered specifically for this indication,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We believe this is an important validation of our platform strategy and we are excited to have the Janssen development team taking the lead in advancing the prostate cancer program. Separately, we look forward to continued progress with our LADD platform in a broad array of other oncology indications, including pancreatic cancer, mesothelioma, non-small cell lung cancer and glioblastoma among others.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.